Investment
Features
FeesSafety
Academy
More
Pluang+

Compare FMC Corp (FMC) vs BIO-TECHNE Corp (TECH) Price & Performance

BIO-TECHNE CorpTrade

Price performance (Past 24H)

Key statistics

FMC Corp vs BIO-TECHNE Corp — how do they compare? FMC Corp trades at $8.89 (market cap $1.39B), while BIO-TECHNE Corp trades at $72.46 (market cap $11.36B). The key difference: BIO-TECHNE Corp is far larger — about 8.2× FMC Corp's market cap, and FMC Corp pays the higher dividend (3.59%). Which is the better fit depends on your goals — on Pluang, investors hold FMC Corp for 68 Days and BIO-TECHNE Corp for 63 Days on average.

FMCTECH
Market Cap
$1.39B$11.36B
Volume
4,145,9795,390,331
Sector
Basic MaterialsHealth
52-Week High
$30.63$72.61
52-Week Low
$8.44$43.31
Typical Hold Time
68 Days63 Days
Enterprise Value
$5.19B$11.39B
Dividend Yield
3.59%0.44%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

FMC Corp

FMC trades at $9.09, up 0.66% with bearish technical signals despite recent earnings beats. The agricultural sciences company faces severe profitability challenges with a -84.83% net margin and negative ROE, though valuation ratios appear attractive with P/S of 0.35 and P/B of 0.86. Recent developments include regulatory filings for new herbicides in Brazil and a minority equity investment from Tessenderlo Group.

While analyst consensus suggests moderate upside to the $14.60 price target, significant operational challenges and negative cash flow from operations in 2025 present substantial risks. The company's aggressive deleveraging efforts and new product pipeline offer potential catalysts, but investors face headwinds from cyclical industry pressures and persistent profitability issues.

BIO-TECHNE Corp

TECH trades at $72.53, near its 52-week high of $72.70, with a bullish technical signal and strong institutional interest. Recent earnings show mixed results, beating in Q2 2026 but missing in Q1. The company maintains solid profitability with a 65.77% gross margin, though net income declined to $73.40M in 2025. Shareholders approved an acquisition by Merck KGaA at $73.00 per share, a key near-term catalyst.

Outlook is positive due to the pending acquisition, but risks include execution challenges and valuation concerns with a high P/E of 62.53. Analyst consensus is divided with 46% buy ratings, suggesting cautious optimism. The stock offers limited upside to the acquisition price, making it suitable for event-driven investors.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

FMC
0% Buy100% Sell
Avg holding period · 68 Days
TECH

No sentiment data available yet.

Top news

Latest headlines on both assets

About FMC Corp

FMC is a pure-play crop chemical company. The company has diversified its sales to create a balanced crop chemical portfolio across geographies and crop exposure. Through acquisitions, FMC is now one of the five largest patented crop chemical companies and will continue to develop new products, with a focus on biologicals, through its research and development pipeline.

Read more on FMC →

About BIO-TECHNE Corp

Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.

Read more on TECH →